In addition sIPV adjuvanted with aluminum hydroxide has been developed for dose sparing purposes to increase the availability and affordability of the vaccine. Based on in vivo immunogenicity results in rats [16] and [17], 10:16:32 D-antigen units (DU) of Sabin-1, -2 and -3, respectively, were selected as the dose that was likely to induce an adequate immune response in humans [15] and [18]. The intended dose of www.selleckchem.com/products/mi-773-sar405838.html adjuvanted sIPV contains 5:8:16 DU of poliovirus type 1:2:3 [19], because aluminum hydroxide is expected to increase

the potency of sIPV by at least a factor 2. Six formulations of sIPV were produced for clinical evaluation: a high, middle and a low dose, each with and without adjuvant (Table 1) [20]. The safety and immunogenicity of high-dose sIPV and high-dose adjuvanted sIPV has been evaluated in humans in a double-blind, randomized, controlled phase I trial in healthy adults with wIPV (NVI) as a comparator. Both sIPV and adjuvanted

sIPV were well-tolerated. sIPV as a booster dose was equally immunogenic as wIPV [21]. Here we present the results of a double-blind, controlled, randomized dose-escalation trial with sIPV and adjuvanted sIPV in 8-week-old infants. This trial evaluated the safety and immunogenicity of three doses, low-, middle- or high-dose sIPV or adjuvanted sIPV (Table PAK6 1), administered with an interval of 8 weeks, with wIPV as a reference. EX 527 A randomized, controlled, double-blind, phase I/IIa dose-escalation trial was performed by monipol sp. z o.o.

at seven sites in Poland. Facilities that participated in this trial were out-patient clinics, child health clinics, pediatric wards, non-public clinics, and vaccination centers. Infants were eligible if they were between 56 and 63 days old at first dose of the investigational medicinal product (IMP) and in good health as determined by the outcome of medical history, physical examination screening and clinical judgment of the investigator. Specifically, subjects should have had no known or suspected disease that affects the immune system, use medication that may influence the immune system, or have a history of any neurological disorder including epilepsy or febrile seizures. Infants of 8 weeks (56–63 days) old received three doses of the IMP with an interval of 8 weeks (±4 days), which replaced the regular IPV from the national immunization schedule (NIS). Other NIS vaccinations were administered at least 14 days before or after vaccination with the IMP. Inclusion and randomization was performed in three steps according to a randomization list prepared by the statistician.